Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.1989
Abstract: Crizotinib and alectinib are anaplastic lymphoma kinase (ALK)‐inhibitors indicated for the treatment of ALK‐positive metastatic non‐small cell lung cancer (NSCLC). At the currently used fixed doses, interindividual variability in exposure is high. The aim of… read more here.
Keywords: lymphoma kinase; anaplastic lymphoma; crizotinib; crizotinib alectinib ... See more keywords
Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.29463
Abstract: In non‐small cell lung cancer, sensitizing mutations in epidermal growth factor receptor (EGFR) or cMET amplification serve as good biomarkers for targeted therapies against EGFR or cMET, respectively. Here we aimed to determine how this… read more here.
Keywords: crizotinib; cell; cell line; hcc827gr5 cell ... See more keywords
Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-020-03476-4
Abstract: Crizotinib is the first-line small molecule tyrosine kinase inhibitor for ALK-positive non-small cell lung cancer. In this study, a retrospective pharmacogenomics investigation was conducted to explore the relationship between genes related to RTK downstream signaling… read more here.
Keywords: crizotinib; alk positive; toxicity; crizotinib induced ... See more keywords
Gaining insight into crizotinib resistance mechanisms caused by L2026M and G2032R mutations in ROS1 via molecular dynamics simulations and free-energy calculations
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Molecular Modeling"
DOI: 10.1007/s00894-017-3314-z
Abstract: AbstractROS1 fusion kinase—highly expressed in a variety of human cancers—has emerged as an important and attractive target for anticancer drug design. Crizotinib, a well-known drug approved by the FDA as an ALK inhibitor to treat… read more here.
Keywords: molecular dynamics; crizotinib; l2026m g2032r; resistance ... See more keywords
Sequential Therapy with Crizotinib and Alectinib in ALK‐Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.07.022
Abstract: Introduction: Alectinib and crizotinib have been approved for the therapy of NSCLC caused by anaplastic lymphoma kinase gene (ALK) rearrangement. The effect of alectinib or crizotinib on overall survival (OS) in patients with ALK‐rearranged NSCLC… read more here.
Keywords: alectinib crizotinib; crizotinib; treated group; crizotinib alectinib ... See more keywords
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.09.001
Abstract: Introduction: Immune checkpoint inhibitors (ICIs) are standard therapies in advanced NSCLC. Although genotype‐directed tyrosine kinase inhibitors represent the standard of care for subsets of oncogene‐driven NSCLC, patients may receive ICIs during their disease course. The… read more here.
Keywords: crizotinib; transaminase level; hepatotoxicity; therapy ... See more keywords
Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.10.161
Abstract: Background: Locally advanced NSCLC is one of the most heterogeneous conditions, with multidimensional treatments involved. Neoadjuvant therapy had been commonly considered an optimal management strategy for patients with operable locally advanced. However, as targeted therapy… read more here.
Keywords: alk; response; crizotinib; neoadjuvant crizotinib ... See more keywords
Optimal management of ALK-positive NSCLC progressing on crizotinib.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.02.003
Abstract: Crizotinib is an anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (-TKI) that represents the standard first-line treatment of patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer (NSCLC). In this setting, crizotinib has demonstrated a response… read more here.
Keywords: nsclc; alk; alk tki; crizotinib ... See more keywords
Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.07.017
Abstract: OBJECTIVES Patients harboring rearrangements of the ROS1 gene are eligible for first-line therapy with Crizotinib, which represents the best available treatment option. Diagnostic criteria, based on break-apart fluorescence in situ hybridization, were mirrored from ALK… read more here.
Keywords: crizotinib; fusion; lung cancer; ros1 ... See more keywords
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.03.005
Abstract: OBJECTIVE In ALTA-1 L, first-line brigatinib versus crizotinib significantly prolonged progression-free survival in advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC). We report health-related quality of life (HRQOL) outcomes from ALTA-1 L. MATERIALS AND METHODS HRQOL was… read more here.
Keywords: alk; crizotinib; brigatinib; lung cancer ... See more keywords
Detailed structural investigation of Crizotinib and the exploration of its antitumor potential by DFT calculations and molecular docking
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Molecular Structure"
DOI: 10.1016/j.molstruc.2021.131530
Abstract: Abstract Detailed structural investigation and exploration of the potential clinical indications are necessary for the drug reevaluation of newly-approved drugs. Crizotinib is a potent and selective receptor tyrosine kinases (RTK) dual inhibitor approved for treatment… read more here.
Keywords: structural investigation; exploration; crizotinib; molecular docking ... See more keywords